Smith & Nephew plc
NYSE•SNN
CEO: Dr. Deepak S. Nath Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1999-11-16
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Contact Information
Building 5, Croxley Park Hatters Lane, Watford, WD18 8YE, United Kingdom
44-1923-477-100
Market Cap
$14.30B
P/E (TTM)
29.3
37.2
Dividend Yield
2.3%
52W High
$38.79
52W Low
$23.91
52W Range
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2025 Data
Revenue
$2.99B+5.68%
4-Quarter Trend
EPS
$0.68+36.00%
4-Quarter Trend
FCF
$259.32M+292.91%
4-Quarter Trend
2024 Annual Earnings Highlights
Key Highlights
Strong Revenue and Profit Growth Underlying revenue grew 5.3% to $5,810M; operating profit surged 54.6% to $657M, showing tangible progress.
Trading Margin Expansion Achieved Trading profit margin hit 18.1%, expanding 60bps, successfully offsetting inflation and China headwinds.
Cash Flow Generation Improved Cash generated from operations increased 50.2% to $1,245M, driven by working capital discipline and lower restructuring costs.
ROIC Shows Strong Improvement Adjusted Return on Invested Capital reached 7.4%, marking a 150bps increase year-over-year, reflecting foundation fixing.
Risk Factors
China VBP Headwinds Impact Trading margin absorbed -490bps headwinds from input cost inflation and China Volume Based Procurement pricing pressures.
Inventory Reduction Remains Focus Year-end inventory position was higher than original expectations; further inventory improvements remain a key focus area for 2025.
Geopolitical and Economic Uncertainty Exposure to global political uncertainty, trade policy changes, and inflation could negatively impact revenue and operating profit.
Cybersecurity and Regulatory Risks Evolving AI regulation, EU MDR compliance, and ongoing cyber threats pose risks to operations and financial condition.
Outlook
2025 Margin Guidance Issued Expect trading profit margin to expand significantly to 19.0% to 20.0% driven by leverage and cost reductions.
Continued Underlying Revenue Growth Guiding for underlying revenue growth around 5.0% in 2025, despite anticipated China VBP headwinds impacting Reconstruction.
Transformation Unlocks Shareholder Value Transformation is on track; 2025 expected to be an inflection point unlocking substantial value for shareholders.
Capital Prioritized for Growth First capital priority is investing in the business for organic growth and meeting sustainability targets for the long term.
Peer Comparison
Revenue (TTM)
FMS$21.68B
$11.61B
ICLR$8.10B
Gross Margin (Latest Quarter)
100.0%
ZBH72.1%
70.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ILMN | $21.64B | 31.4 | 30.0% | 41.7% |
| ZBH | $17.30B | 21.5 | 6.4% | 34.5% |
| MEDP | $17.21B | 41.0 | 91.9% | 8.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.0%
Moderate Growth
4Q Net Income CAGR
48.1%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 23, 2026
EPS:-
|Revenue:-
Reports
All Years
Form 20-F - FY 2024
Period End: Dec 31, 2024|Filed: Mar 10, 2025|Revenue: $5.81B+4.7%|EPS: $0.94-21.7%MeetForm 20-F - FY 2023
Period End: Dec 31, 2023|Filed: Mar 11, 2024|Revenue: $5.55B+6.4%|EPS: $1.20+140.0%BeatForm 20-F - FY 2022
Period End: Dec 31, 2022|Filed: Mar 6, 2023|Revenue: $5.22B+0.1%|EPS: $0.50-58.3%MissForm 20-F - FY 2021
Period End: Dec 31, 2021|Filed: Mar 7, 2022|Revenue: $5.21B+14.3%|EPS: $1.20+17.6%MissForm 20-F - FY 2020
Period End: Dec 31, 2020|Filed: Mar 1, 2021|Revenue: $4.56B-11.3%|EPS: $1.02-26.1%Meet